Contrast-induced acute kidney injury following PCI

被引:70
|
作者
Tehrani, Shana [1 ]
Laing, Chris [2 ]
Yellon, Derek M. [1 ]
Hausenloy, Derek J. [1 ]
机构
[1] UCL, Hatter Cardiovasc Inst, London WC1E 6HX, England
[2] Royal Free Hosp, UCL Ctr Nephrol, London, England
关键词
Biomarkers of acute kidney injury; contrast-induced acute kidney injury; percutaneous coronary intervention; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; ACUTE-RENAL-FAILURE; INDUCED NEPHROPATHY; SODIUM-BICARBONATE; RISK-FACTORS; N-ACETYLCYSTEINE; ANEURYSM REPAIR; HIGH-OSMOLAR; PREVENTION;
D O I
10.1111/eci.12061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Coronary revascularization using percutaneous coronary intervention (PCI) is one of the major treatments for patients with stable coronary artery disease, with approximately 1.5 million patients undergoing PCI in the United States and Europe every year. An important neglected complication of PCI is contrast-induced acute kidney injury (CI-AKI). Design In this article, we review the definition, pathogenesis and management of CI-AKI and highlight potential therapeutic options for preventing CI-AKI in post-PCI patients. Results CI-AKI is an important but underdiagnosed complication of PCI that is associated with increased in-hospital morbidity and mortality. Patients with pre-existing renal impairment and diabetes are particularly susceptible to this complication post-PCI. Optimization of the patients' circulating volume remains the mainstay for preventing CI-AKI, although the best strategy for achieving this is still controversial. Conclusion Following PCI, CI-AKI is an overlooked complication which is associated with significant morbidity and mortality. In this article, we review the pathophysiology of CI-AKI in patients undergoing PCI and discuss the potential therapeutic options for preventing it.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 50 条
  • [31] Cystatin C and Contrast-Induced Acute Kidney Injury
    Briguori, Carlo
    Visconti, Gabriella
    Rivera, Natalia V.
    Focaccio, Amelia
    Golia, Bruno
    Giannone, Rosalia
    Castaldo, Diletta
    De Micco, Francesca
    Ricciardelli, Bruno
    Colombo, Antonio
    CIRCULATION, 2010, 121 (19) : 2117 - 2122
  • [32] Renalase and Biomarkers of Contrast-Induced Acute Kidney Injury
    Wybraniec, Maciej T.
    Mizia-Stec, Katarzyna
    CARDIORENAL MEDICINE, 2016, 6 (01) : 25 - 36
  • [33] Statins for the Prevention of Contrast-Induced Acute Kidney Injury
    Ball, Timothy
    McCullough, Peter A.
    NEPHRON CLINICAL PRACTICE, 2014, 127 (1-4): : 165 - 171
  • [34] Strategies for the prevention of contrast-induced acute kidney injury
    Weisbord, Steven D.
    Palevsky, Paul M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (06): : 539 - 549
  • [35] Multimodality prevention of contrast-induced acute kidney injury
    McCullough, Peter A.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (02) : 169 - 172
  • [36] Multimodality prevention of contrast-induced acute kidney injury
    Briguori, Carlo
    Airoldi, Flavio
    Colombo, Antonio
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (06) : 1068 - 1068
  • [37] Understanding and preventing contrast-induced acute kidney injury
    Faehling, Michael
    Seeliger, Erdmann
    Patzak, Andreas
    Persson, Pontus B.
    NATURE REVIEWS NEPHROLOGY, 2017, 13 (03) : 169 - 180
  • [38] Novel Biomarkers for Contrast-Induced Acute Kidney Injury
    Briguori, Carlo
    Quintavalle, Cristina
    Donnarumma, Elvira
    Condorelli, Gerolama
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [39] Tolvaptan Improves Contrast-Induced Acute Kidney Injury
    Xu, Chunyang
    Huang, Xu
    Yan, Gaoliang
    Wang, Dong
    Hu, Meijuan
    Tang, Chengchun
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2022, 2022
  • [40] Prevention of Contrast-Induced Acute Kidney Injury: an Update
    George Chalikias
    Ioannis Drosos
    Dimitrios N. Tziakas
    Cardiovascular Drugs and Therapy, 2016, 30 : 515 - 524